Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Prevention of transplant rejection can tolerance be achieved with immunosuppressive treatment?

Delaney, CP and Murase, N and Starzl, TE and Demetris, AJ (1996) Prevention of transplant rejection can tolerance be achieved with immunosuppressive treatment? Clinical Immunotherapeutics, 6 (2). 89 - 96. ISSN 1172-7039

Accepted Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Successful solid organ transplantation is generally attributed to the increasingly precise ability of drugs to control rejection. However, it was recently shown that a few donor haematolymphoid cells can survive for decades in recipients of successful organ allografts, a phenomenon called microchimaerism. The association for decades of haematolymphoid chimaerism with allograft tolerance in experimental transplantation suggests that immunosuppressive drugs merely create a milieu that enables an allograft and its complement of passenger leucocytes to prime the recipient for graft acceptance. Exploitation of this concept requires a fundamental shift in the classical view of passenger leucocytes only as initiators of rejection. Microchimaerism has taught us that solid organ transplantation involves the transfep-öTEwo3öTK}r organ systems to the recipient: the allograft parenchyma an-4oHg-4oonor'-4y&eWtolymphoid system in the form of donor stem cells contajfletwit|4Q(Xj pas-4MTger leucocyte compartment. Each has the potential to integral witty-4-4orrespSnping recipient system and carry out normal physiologi|:a£futy-4ijj£jvwlta5irnmunological self definition. Resistance to initial integralen r-4WMjure £als requires some form of immunosuppression, but mainterçad-4 of donor-4Rjraiine system function will depend on renewable supply of cells, v-4Jrf-4Siyi-4jj-4fvided by engrafted progenitors. Successful clinical application willctepcrrtTon the development of low morbidity methods to enhance engraftment of donor haemopoietic stem cells. Adis international Limited All rights reserved.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Delaney, CP
Murase, N
Starzl, TEtes11@pitt.eduTES11
Demetris, AJ
Centers: Other Centers, Institutes, Offices, or Units > Thomas E. Starzl Transplantation Institute
Date: 1 January 1996
Date Type: Publication
Journal or Publication Title: Clinical Immunotherapeutics
Volume: 6
Number: 2
Page Range: 89 - 96
DOI or Unique Handle: 10.1007/bf03259505
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 1172-7039
Other ID: uls-drl:31735062133594, Starzl CV No. 1894
Date Deposited: 08 Apr 2010 17:32
Last Modified: 27 Jan 2019 02:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item